

Approved



Lesotho
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		301,982		301,982	58,497	360,479
USAID		14,912,256	6,400,000	21,312,256	6,386,291	27,698,547
DOD		928,598		928,598	56,883	985,481
PC		687,000		687,000	0	687,000
HHS/CDC	512,500	16,951,345		17,463,845	3,729,648	21,193,493
State/AF		150,000		150,000	0	150,000
Total	512,500	33,931,181	6,400,000	40,843,681	10,231,319	51,075,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						On Hold Amount	Total
	State	DOD	HHS/CDC	PC	State/AF	USAID		
CIRC		425,528				138,579	0	564,107
HBHC		2,824	864,014		60,000	1,216,138	0	2,142,976
HKID				235,487	30,000	2,723,241	0	2,988,728
HLAB		2,824	576,442				0	579,266
HTXS		178,419	8,927,361			8,849,049	0	17,954,829
HVCT		12,618	2,333,413			475,818	0	2,821,849
HVMS	301,982	50,255	562,499	85,389		2,348,451	0	3,348,576
HVOP		2,824		366,124		461,448	0	830,396
HVSI		252,824	929,700			299,808	0	1,482,332
HVTB			1,236,437			1,656,829	0	2,893,266
MTCT			277,984			572,656	0	850,640
OHSS			73,100			405,122	0	478,222

Approved



PDCS			392,396		60,000	627,988	0	1,080,384
PDTX		482	1,290,499			1,537,129	0	2,828,110
	301,982	928,598	17,463,845	687,000	150,000	21,312,256	0	40,843,681



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	2,110,173	0
HKID	2,772,599	0
HVTB	2,761,290	0
PDCS	1,034,179	0
Total Technical Area Planned Funding:	8,678,241	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	527,076	0
HVSI	986,640	0
OHSS	359,873	0
Total Technical Area Planned Funding:	1,873,589	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	422,704	0
HVCT	2,788,448	0
HVOP	477,826	0
MTCT	790,679	0
Total Technical Area Planned Funding:	4,479,657	0

Technical Area: Treatment

Approved



Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	17,800,339	0
PDTX	2,781,905	0
Total Technical Area Planned Funding:	20,582,244	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	34,593
	Number of new ANC and L&D clients	38,509
	By: Known positives at entry	5,523
	By: Number of new positives identified	3,591
	Sum of Positives Status disaggregates	9,114
	Required only for DREAMS Countries - By Number of new positives: <15	16
	Required only for DREAMS Countries - By Number of new positives: 15-19	757
	Required only for DREAMS Countries - By Number of new positives: 20-24	1,107
	Required only for DREAMS Countries - By Number of known positives: <15	28
	Required only for DREAMS Countries - By Number of known	1,252



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	1,612
	Required only for DREAMS Countries - Denominator: <15	303
	Required only for DREAMS Countries - Denominator: <15-19	8,327
	Required only for DREAMS Countries - Denominator: 20-24	11,118
	Required only for DREAMS Countries - Denominator: 25-49	14,878
	Required only for DREAMS Countries - Denominator: 50+	8
	Required only for DREAMS Countries - By Number of known positives: 25-49	2,311
	Required only for DREAMS Countries - By Number of known positives: 50+	1
	Required only for DREAMS Countries - By Number of new positives: 25-49	1,464
	Required only for DREAMS Countries - By Number of new positives: 50+	2
	By Age (DREAMS SNUs ONLY): <15	252
	By Age (DREAMS SNUs ONLY): 15-19	7,863
	By Age (DREAMS SNUs ONLY): 20-24	10,496
	By Age (DREAMS SNUs ONLY): 25-49	14,131



	By Age (DREAMS SNU's ONLY): 50+	15
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	34,593
	New on ART	8,819
	Already on ART at beginning of current pregnancy	5,644
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	40,573
	By Age: 0-60 days	0
	By Age: 2 months - 9 years	0
	By Age: 10-14	1,101
	By Age: 15-19	12,761
	By Age: 20-24	13,069
	By Age: 25-29	12,907
	By Age: 30-49	551
	By Age: 50+	184
	Sum of age disaggregates (Prior to FY15)	27,115
	Sum of age disaggregates (FY15-Current)	40,573
By HIV status: Number of		



	HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	34,573
	By circumcision technique: Device-based VMMC	6,000
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	93,403
	Total number of people in the	567,920



	target population	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	11,170
	Aggregated Age/sex: 15+ Male	40,605



	Aggregated Age/sex: <15 Female	5,972
	Aggregated Age/sex: 15+ Female	37,313
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	372
	Total number of people in the target population	154,388
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Age/sex: <15 Male	276
	Aggregated Age/sex: 15+ Male	316
	Aggregated Age/sex: <15 Female	101
	Aggregated Age/sex: 15+ Female	124
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are	n/a



	based on evidence and/or meet the minimum standards required (DSD)	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,459
	Total estimated number of key population in the catchment area	6,571
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,380
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex	



	<p>workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>2,079</p>
	<p>By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are</p>	



	based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	5,021
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,300
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	



	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	898,450
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	34,184
	Age/sex: 15-19 Male	31,468
	Age/sex: 20-24 Male	56,779
	Age/sex: 25-49 Male	201,571
	Age/sex: 50+ Male	57,885
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	34,981
	Age/sex: 15-19 Female	24,500
	Age/sex: 20-24 Female	53,513
	Age/sex: 25-49 Female	209,707
	Age/sex: 50+ Female	86,058
	Test Result by Age and Sex: Positive: 10-14 Male	1,377
Test Result by Age and Sex:	1,801	



	Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	3,473
	Test Result by Age and Sex: Positive: 25-49 Male	26,766
	Test Result by Age and Sex: Positive: 50+ Male	7,246
	Test Result by Age and Sex: Positive: 10-14 Female	1,450
	Test Result by Age and Sex: Positive: 15-19 Female	2,567
	Test Result by Age and Sex: Positive: 20-24 Female	4,679
	Test Result by Age and Sex: Positive: 25-49 Female	32,478
	Test Result by Age and Sex: Positive: 50+ Female	10,589
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex:	



	Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	40,279
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	202,230
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	49,730
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	211,500
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	1,913
	Test Result by Aggregated Age and Sex: Positive 15+ Male	25,116
	Test Result by Aggregated Age and Sex: Positive <15 Female	2,442
	Test Result by Aggregated Age and Sex: Positive 15+ Female	30,238
	Test Result by Age: Positive: <1	521
	Test Result by Age: Positive: 1-9	3,173
	Age/sex: <1	13,937
	Age/sex: 1-9	88,224
	Service Delivery Point	28,969



	(Community): Index testing	
	Service Delivery Point	77,907
	(Community): Homebased testing	
	Service Delivery Point	137,441
	(Community): Mobile testing	
	Service Delivery Point	4,449
	(Community): Other	
	Service Delivery Point (Community)	
	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	4,664
	Service Delivery Point (Facility): Outpatient	364,231
	Service Delivery Point (Facility): Pediatric	64,069
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	65,285
	Service Delivery Point (Facility):	1,260



VCT	
Service Delivery Point (Facility): VMMC	33,358
Service Delivery Point (Facility): PMTCT	95,401
Service Delivery Point (Facility): TB Clinics	32,403
Service Delivery Point (Facility): Index testing	0
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by	



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	13,662
	Total number of registered new and relapsed TB cases, during the reporting period.	13,662
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24	



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	532
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,423
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	400
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,307
	Result: Known HIV positive at service entry	



	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	89,866



	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	9,844
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	32,805
	Sum of Age/Sex disaggregates	42,649
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	784
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	200
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	168
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	197
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	234
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	632
	Required only for DREAMS	144



	countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	92
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	108
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	80
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	784
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	7,891
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	7,929
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	842
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	16,375
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	632



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	144
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	92
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	108
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	80
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS	



	countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	4,075
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	3,692
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	6,760
	Required only for DREAMS	



	countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS	



	countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	1,720
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	1,720
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	



	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	34
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	30
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	1,616
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	1,616
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	100
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	



	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By age/sex: 18-24 Male	
	By age/sex: 25+ Male	
	Age/Sex: 18+ Male	18
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By age/sex: 18-24 Female	
	By age/sex: 25+ Female	
	Age/Sex: 18+ Female	18
	Sum of Age/Sex disaggregates	36
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	27
	Required only for DREAMS countries: By Service Area, age and sex: Education Support	31



	Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	4
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	58
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	2
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Education Support Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	28
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	48
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	44
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	162
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	127
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	497
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9	



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	23
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	20
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	20
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+	30
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	20
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	20
	Required only for DREAMS countries: By Service Area, age	30



	and sex: Social Protection Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	123
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	27
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	32
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	52
	Required only for DREAMS	



	countries: By Service Area, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	33
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	124
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	127
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	497
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4	



	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	50
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	50
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	55
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	86
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support 1-9	8
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	38
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening	



	1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas <1	12
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	50
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	50
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	78
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	343
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Program 1-9 Female	
	Required only for DREAMS countries - By service, age and	



	sex: Economic Strengthening 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Other Service Areas 1-9 Female	112
	Required only for DREAMS countries - By service, age and sex: Social Protection 1-9 Female	17
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas 1-9	106
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	9,151
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	9,336
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB	



	cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	343



	ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,983
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	258
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,569
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	163,029
	Screened for TB by Age/Sex:<15 Male	4,301
	Screened for TB by Age/Sex: 15+ Male	54,313
	Screened for TB by Age/Sex:<15 Female	4,372



	Screened for TB by Age/Sex: 15+ Female	100,044
	Screen Result: Screened Positive for TB	7,554
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	7,691
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	310
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	7,381
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	7,244



	By infants who received their first virologic HIV test between 2 and 12 months of age	2,669
	Sum of Infant Age disaggregates	9,913
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	119
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	38
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	192,499
	Age/Sex: 15-19 Male	2,437
	Age/Sex: 15-19 Female	3,928
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	6,222
	Aggregated Age/Sex: 15+ Male	72,250
	Aggregated Age/Sex: <15 Female	6,822
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	107,200



	Sum of Aggregated Age/Sex <15	13,044
	Sum of Aggregated Age/Sex 15+	179,450
	Sum of Aggregated Age/Sex disaggregates	192,494
	Age/Sex: <1	783
	Age/Sex: <1-9	7,121
	Age/Sex: 10-14 Male	2,455
	Age/Sex: 10-14 Female	2,647
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	4,537
	Age/Sex: 25-49 Male	51,965
	Age/Sex: 50+ Male	12,184
	Age/Sex: 20-24 Female	7,264
	Age/Sex: 25-49 Female	74,258
	Age/Sex: 50+ Female	20,982
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	89,811
	By Age/Sex: <1	352
	By Age/Sex: 1-9	2,790
	By Age/Sex: 10-14 Male	998
	By Age/Sex: 15-19 Male	983
	By Age/Sex: 20-24 Male	2,270
	By Age/Sex: 25-49 Male	26,678
	By Age/Sex: 50+ Male	6,107
	By Age/Sex: 10-14 Female	1,017
	By Age/Sex: 15-19 Female	1,513
	By Age/Sex: 20-24 Female	3,259
	By Age/Sex: 25-49 Female	33,846
	By Age/Sex: 50+ Female	9,628



	Sum of Age/Sex disaggregates	86,299
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	2,553
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	36,270
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	2,580
	Aggregated Grouping by Age/Sex: 15+ Female	48,407
	Sum of Aggregated Age/Sex disaggregates	89,810
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory	223,751



	results within the past 12 months.	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	248,708
	Numerator: Indication: Routine	223,751
	Numerator: Indication: Targeted	0
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	



	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	



	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	248,708
	Denominator: Indication: Targeted	0
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	



	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	



	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	6,514
	Numerator Aggregated Age/Sex: 15+ Male	77,859
	Numerator Aggregated Age/Sex: <15 Female	7,327
	Numerator Aggregated Age/Sex: 15+ Female	132,047
	Denominator Aggregated Age/Sex: <15 Male	8,054
	Denominator Aggregated Age/Sex: 15+ Male	86,529
	Denominator Aggregated Age/Sex: <15 Female	8,115
	Denominator Aggregated Age/Sex: 15+ Female	145,526



TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	53,802
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	65,560
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	573
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,069
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	723
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	290
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	890
	Age/Sex: 25-49 Male (Numerator:	13,504



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,510
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	739
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,581
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,547
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20,749
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,316
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have	697



	died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,377
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	886
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	354
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,091
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated	16,474



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,060
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	897
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,923
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	6,752



	those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25,409
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,273
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated	



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,182
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,394
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,043
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32,181
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	2,428



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21,192
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,428
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	39,512
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that	9



	perform this testing	
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	9
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	CD4: Number of laboratories that perform this testing	9
	CD4: Number of laboratories that participate in this PT program	9
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	Early infant diagnostics: Number of laboratories that perform this testing	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that perform this testing	1
	HIV viral load: Number of laboratories that participate in this PT program	1
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1



	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	9
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	9
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	9
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	9
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing	



	(PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	15
	CD4: Number of laboratories that participate in this PT program	15
	CD4: Number of laboratories that perform this testing	15
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that perform this testing	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	92
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	92
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	92
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	HIV viral load: Number of laboratories that participate in this PT program	0



	HIV viral load: Number of laboratories that perform this testing	0
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	0
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
INVS_COMD	PEPFAR resources used for HIV-program related commodities:	2,200,000



	planned & purchased in the last 12 months by Implementing Partner	
	Number of HIV Test Kits purchased	
	Number of HIV CD4 Reagents purchased	400,000
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	1,800,000
	Number of HIV ARVs purchased	
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	400,000
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	1,800,000
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7455	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	250,000
11018	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	137,000
11030	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
13981	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14301	Population Services International	NGO	U.S. Agency for International Development	GHP-USAID	395,826
16766	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	5,002,649
16768	Mothers 2 Mothers	NGO	U.S. Agency for International Development	GHP-USAID	1,600,000
17123	Columbia University	University	U.S. Department of Health and Human	GHP-State	1,456,640



			Services/Centers for Disease Control and Prevention		
17401	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,597,181
17429	Population Services International	NGO	U.S. Department of Defense	GHP-State	608,574
17431	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,128,266
17432	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,572,811
17549	JHPIEGO	University	U.S. Agency for International Development	GHP-State	109,873
18020	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	9,030,719
18048	Global Health Supply Chain	Private Contractor	U.S. Agency for International Development	GHP-USAID	1,000,000

Approved



	Program		Development		
18143	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	0
18227	TBD	TBD	Redacted	Redacted	Redacted
18235	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	1,000,000
18240	Vodafone Foundation	NGO	U.S. Agency for International Development	GHP-USAID	0



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 7455	Mechanism Name: LDF, Department of Defense Support
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source	Funding Amount
GHP-State	250,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	7455		
Mechanism Name:	LDF, Department of Defense Support		
Prime Partner Name:	U.S. Department of Defense (Defense)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	250,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11018	Mechanism Name: Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 137,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 137,000	
Funding Source	Funding Amount
GHP-State	137,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	10,250
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	10,250
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Education	10,250
Water	10,000

Budget Code Information



Mechanism ID: 11018			
Mechanism Name: Peace Corps			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	55,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	82,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,237
PP_PREV_TA	Total number of people in the target population	227,914
PP_PREV_TA	Aggregated Age/sex: <15 Male	405
PP_PREV_TA	Aggregated Age/sex: 15+ Male	452
PP_PREV_TA	Aggregated Age/sex: <15 Female	567
PP_PREV_TA	Aggregated Age/sex: 15+ Female	741
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,297
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,139
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,849
OVC_SERV_TA	Age/Sex: 18+ Male	686
OVC_SERV_TA	Age/Sex: 18+ Female	693
OVC_SERV_TA	Sum of Age/Sex disaggregates	1,379
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	27
OVC_SERV_TA	Required only for DREAMS countries: By Service Area,	31



	age and sex: Education Support Female 15-17	
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	4
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	58
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	2
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	81
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	81
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	127
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	162
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	127
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	497
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	23
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	20
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	20
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+	30
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	20
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	20
OVC_SERV_TA	Required only for DREAMS countries: By Service Area,	30



	age and sex: Social Protection Male 18-24	
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	123
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	81
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	81
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	127
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	33
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	124
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	127
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	497
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	50
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	50
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	55
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	86
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support 1-9	8
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	38
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas <1	12
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	50
OVC_SERV_TA	Required only for DREAMS countries: By Service Area,	50



	age and sex: Other Service Areas Male 15-17	
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	78
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	343
OVC_SERV_TA	Required only for DREAMS countries - By service, age and sex: Other Service Areas 1-9 Female	112
OVC_SERV_TA	Required only for DREAMS countries - By service, age and sex: Social Protection 1-9 Female	17
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas 1-9	106

Implementing Mechanism Details

Mechanism ID: 11030	Mechanism Name: PEPFAR Small Grants Program
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-State	150,000

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	100,000
Education	50,000
Gender: Gender Equality	30,000
Focus Area:	Increase gender-equitable access to income and



	productive resources, including education
Sub Area:	Capacity building

Budget Code Information

Mechanism ID: 11030			
Mechanism Name: PEPFAR Small Grants Program			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	60,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,000
OVC_SERV_DSD	Age/Sex: 18+ Male	34
OVC_SERV_DSD	Age/Sex: 18+ Female	34
OVC_SERV_DSD	Sum of Age/Sex disaggregates	68
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0



OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	450
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	482

Implementing Mechanism Details

Mechanism ID: 13981	Mechanism Name: TARGET: Increasing access to HIV counseling, testing and enhancing HIV/AIDS prevention	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Services International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13981		
Mechanism Name:	TARGET: Increasing access to HIV counseling, testing and enhancing HIV/AIDS prevention		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	115,334
HTC_TST_DSD	Age/sex: 10-14 Male	4,423
HTC_TST_DSD	Age/sex: 15-19 Male	4,983
HTC_TST_DSD	Age/sex: 20-24 Male	18,826
HTC_TST_DSD	Age/sex: 25-49 Male	18,268
HTC_TST_DSD	Age/sex: 50+ Male	3,318
HTC_TST_DSD	Age/sex: 10-14 Female	4,797
HTC_TST_DSD	Age/sex: 15-19 Female	3,598
HTC_TST_DSD	Age/sex: 20-24 Female	20,397
HTC_TST_DSD	Age/sex: 25-49 Female	19,794
HTC_TST_DSD	Age/sex: 50+ Female	4,794
HTC_TST_DSD	Sum of Age/Sex disaggregates	103,198
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	70
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	481
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	601
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	902
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	874
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	102
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	561
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	923
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,158
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	1,148
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,970
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	45,393



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11,391
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	48,583
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	21,361
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	93,976
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	115,337
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	143
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,860
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	202
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,793
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	177
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	12,136
HTC_TST_DSD	Service Delivery Point (Community): Index testing	15,601
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	40,371
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	57,663
HTC_TST_DSD	Service Delivery Point (Community): Other	1,699

Implementing Mechanism Details

Mechanism ID: 14301	Mechanism Name: LETLAMA
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 395,826	
---	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 395,826	
Funding Source	Funding Amount
GHP-USAID	395,826

Cross-Cutting Budget Attribution(s)

Condom programming	10,000
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current



	PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

Mechanism ID:	14301		
Mechanism Name:	LETLAMA		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	395,826	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	78,399
PP_PREV_DSD	Total number of people in the target population	549,905
PP_PREV_DSD	Aggregated Age/sex: <15 Male	11,170
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	40,605
PP_PREV_DSD	Aggregated Age/sex: <15 Female	2,305
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	24,319
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,459



KP_PREV_DSD	Total estimated number of key population in the catchment area	6,571
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,380
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,079
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	5,021
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,300
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	62

Implementing Mechanism Details

Mechanism ID: 16766	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 5,002,649	
Applied Pipeline Amount: 294,950	
Total All Funding Sources and Applied Pipeline Amount: 5,297,599	
Funding Source	Funding Amount



GHP-State	5,002,649
-----------	-----------

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	30,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Equity in HIV prevention, care, treatment and support
Food and Nutrition: Policy, Tools, and Service Delivery	50,000
Water	50,000

Budget Code Information

Mechanism ID: 16766			
Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)			
Prime Partner Name: University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,687,599	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	180,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,935,050	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	50,000	0
-----------	------	--------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	54,171
OVC_SERV_DSD	Age/Sex: 18+ Male	9,685
OVC_SERV_DSD	Age/Sex: 18+ Female	9,558
OVC_SERV_DSD	Sum of Age/Sex disaggregates	19,243
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	18,418
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	16,510

Implementing Mechanism Details

Mechanism ID: 16768	Mechanism Name: Mentor Mothers Reducing Infections Through Support and Education (RISE)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Mothers 2 Mothers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,600,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,600,000	
Funding Source	Funding Amount
GHP-USAID	1,600,000

Cross-Cutting Budget Attribution(s)



Gender: GBV	40,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Human Resources for Health	300,000
Gender: Gender Equality	50,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Water	40,000

Budget Code Information

Mechanism ID:	16768		
Mechanism Name:	Mentor Mothers Reducing Infections Through Support and Education (RISE)		
Prime Partner Name:	Mothers 2 Mothers		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	200,000	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,911
PMTCT_ART_DSD	New on ART	6,437
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,186
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,911
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,876
PMTCT_STAT_DSD	By: Known positives at entry	451
PMTCT_STAT_DSD	By: Number of new positives identified	374
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	825
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	24,931
PP_PREV_DSD	Total number of people in the target population	29,928
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	0
PP_PREV_DSD	Aggregated Age/sex: <15 Female	4,442
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	20,489
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,975
OVC_SERV_DSD	Age/Sex: 18+ Male	188
OVC_SERV_DSD	Age/Sex: 18+ Female	431
OVC_SERV_DSD	Sum of Age/Sex disaggregates	619
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	784
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	200
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	168



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	197
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	234
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	632
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	144
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	92
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	108
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	80
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	784
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	200
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	168
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	197
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	234
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	632
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	144
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	92
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	108
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	80



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	1,720
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	1,720
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,588
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	2,768
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	1,616
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	1,616
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	553
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	188
PMTCT_EID_DSD	Sum of Infant Age disaggregates	741
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	8,909
TX_CURR_DSD	Age/Sex: 15-19 Male	860
TX_CURR_DSD	Age/Sex: 15-19 Female	1,572
TX_CURR_DSD	Sum of age/sex disaggregates	2,432
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,975
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,478
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,502
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,783
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	6,477
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,261
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	10,738
TX_CURR_DSD	Age/Sex: <1	130
TX_CURR_DSD	Age/Sex: <1-9	2,396



TX_CURR_DSD	Age/Sex: 10-14 Male	1,879
TX_CURR_DSD	Age/Sex: 10-14 Female	2,072
TX_CURR_DSD	Age/Sex: 20-24 Female	0
TX_CURR_DSD	Age/Sex: 25-49 Female	0
TX_CURR_DSD	Age/Sex: 50+ Female	0

Implementing Mechanism Details

Mechanism ID: 17123	Mechanism Name: CDC HMIS support to the MOH	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Columbia University		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 1,456,640	
Applied Pipeline Amount: 50,000	
Total All Funding Sources and Applied Pipeline Amount: 1,506,640	
Funding Source	Funding Amount
GHP-State	1,456,640

Cross-Cutting Budget Attribution(s)

Human Resources for Health	75,000
----------------------------	--------

Budget Code Information

Mechanism ID: 17123			
Mechanism Name: CDC HMIS support to the MOH			
Prime Partner Name: Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	736,640	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	720,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17401	Mechanism Name: Strengthening Tuberculosis and HIV Response in Lesotho (STAR-L)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 6,597,181	
Applied Pipeline Amount: 1,879,559	
Total All Funding Sources and Applied Pipeline Amount: 8,476,740	
Funding Source	Funding Amount
GHP-State	6,597,181

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
Food and Nutrition: Policy, Tools, and Service Delivery	50,000
Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Gender: Gender Equality	120,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Water	200,000

Budget Code Information

Mechanism ID: 17401			
Mechanism Name: Strengthening Tuberculosis and HIV Response in Lesotho (STAR-L)			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	544,362	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	733,993	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	376,170	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	259,368	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	277,984	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	3,739,370	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	665,934	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,063
PMTCT_ART_DSD	New on ART	1,637
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,137
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,063
PMTCT_STAT_DSD	Number of new ANC and L&D clients	13,753
PMTCT_STAT_DSD	By: Known positives at entry	1,798
PMTCT_STAT_DSD	By: Number of new positives identified	1,122
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,920
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	233
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	375
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	11
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	376
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	595
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator:	137



	<15	
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	2,889
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	4,542
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	6,186
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	815
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	504
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	132
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	2,743
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	4,312
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	5,877
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	232,418
HTC_TST_DSD	Age/sex: 10-14 Male	3,366
HTC_TST_DSD	Age/sex: 15-19 Male	2,445
HTC_TST_DSD	Age/sex: 20-24 Male	7,139
HTC_TST_DSD	Age/sex: 25-49 Male	67,282
HTC_TST_DSD	Age/sex: 50+ Male	11,573
HTC_TST_DSD	Age/sex: 10-14 Female	3,503
HTC_TST_DSD	Age/sex: 15-19 Female	3,986
HTC_TST_DSD	Age/sex: 20-24 Female	12,154



HTC_TST_DSD	Age/sex: 25-49 Female	89,187
HTC_TST_DSD	Age/sex: 50+ Female	20,579
HTC_TST_DSD	Sum of Age/Sex disaggregates	221,214
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	144
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	323
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	947
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	8,940
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	1,540
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	144
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	530
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,614
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	11,853
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	2,733
HTC_TST_DSD	Test Result by Age: Positive: <1	124
HTC_TST_DSD	Test Result by Age: Positive: 1-9	327
HTC_TST_DSD	Age/sex: <1	541
HTC_TST_DSD	Age/sex: 1-9	10,663
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	2,320
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	166,029
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	64,069
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,407
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,407
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	260
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,378
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	181

TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,588
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,941
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,941
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	181
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,577
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	122
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,063
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	67,598
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,934
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	22,283
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,009
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	41,373
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3,378
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,378



TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,378
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,082
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	694
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,776
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	55
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	8
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	71,158
TX_CURR_DSD	Age/Sex: 15-19 Male	765
TX_CURR_DSD	Age/Sex: 15-19 Female	1,247
TX_CURR_DSD	Sum of age/sex disaggregates	2,012
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,034
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	27,647
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,111
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	39,367
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,145
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	67,014
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	71,159
TX_CURR_DSD	Age/Sex: <1	124
TX_CURR_DSD	Age/Sex: <1-9	2,447
TX_CURR_DSD	Age/Sex: 10-14 Male	770
TX_CURR_DSD	Age/Sex: 10-14 Female	803
TX_CURR_DSD	Age/Sex: 20-24 Male	2,230
TX_CURR_DSD	Age/Sex: 25-49 Male	21,034



TX_CURR_DSD	Age/Sex: 50+ Male	3,619
TX_CURR_DSD	Age/Sex: 20-24 Female	3,802
TX_CURR_DSD	Age/Sex: 25-49 Female	27,884
TX_CURR_DSD	Age/Sex: 50+ Female	6,434
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	30,972
TX_NEW_DSD	By Age/Sex: <1	80
TX_NEW_DSD	By Age/Sex: 1-9	1,425
TX_NEW_DSD	By Age/Sex: 10-14 Male	452
TX_NEW_DSD	By Age/Sex: 15-19 Male	328
TX_NEW_DSD	By Age/Sex: 20-24 Male	948
TX_NEW_DSD	By Age/Sex: 25-49 Male	8,963
TX_NEW_DSD	By Age/Sex: 50+ Male	1,533
TX_NEW_DSD	By Age/Sex: 10-14 Female	471
TX_NEW_DSD	By Age/Sex: 15-19 Female	529
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,619
TX_NEW_DSD	By Age/Sex: 25-49 Female	11,881
TX_NEW_DSD	By Age/Sex: 50+ Female	2,743
TX_NEW_DSD	Sum of Age/Sex disaggregates	29,467
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,197
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	11,773
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,224
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	16,778
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	30,972
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	57,637
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	64,038
TX_PVLS_DSD	Numerator: Indication: Routine	57,637
TX_PVLS_DSD	Numerator: Indication: Targeted	0



TX_PVLS_DSD	Denominator: Indication: Routine	64,038
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,645
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	19,003
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,711
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	35,279
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,827
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	21,111
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,904
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	39,196
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	18,376
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	22,404
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	226
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,375
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	373
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	100
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	305
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,710



TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,020
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	392
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	370
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,921
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,360
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,224
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	272
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,530
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	455
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	115



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	376
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,747
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,244
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	473
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	456
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,343
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	7,889



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,501
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,310
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,134
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,177
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,755
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,365
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,482
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,365
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	12,192



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	--	--

Implementing Mechanism Details

Mechanism ID: 17429	Mechanism Name: LDF Comprehensive Clinical Support Program
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 608,574	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 608,574	
Funding Source	Funding Amount
GHP-State	608,574

Cross-Cutting Budget Attribution(s)

Condom procurement	10,000
Condom programming	10,000

Budget Code Information

Mechanism ID: 17429			
Mechanism Name: LDF Comprehensive Clinical Support Program			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	CIRC	422,704	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	12,618	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	172,770	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	482	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	4,492
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	1,101
VMMC_CIRC_DSD	By Age: 15-19	531
VMMC_CIRC_DSD	By Age: 20-24	1,594
VMMC_CIRC_DSD	By Age: 25-29	531
VMMC_CIRC_DSD	By Age: 30-49	551
VMMC_CIRC_DSD	By Age: 50+	184
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	3,410
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	4,492
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	4,492
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,926
HTC_TST_DSD	Age/sex: 10-14 Male	978



HTC_TST_DSD	Age/sex: 15-19 Male	1,571
HTC_TST_DSD	Age/sex: 20-24 Male	1,834
HTC_TST_DSD	Age/sex: 25-49 Male	1,559
HTC_TST_DSD	Age/sex: 50+ Male	262
HTC_TST_DSD	Age/sex: 10-14 Female	14
HTC_TST_DSD	Age/sex: 15-19 Female	140
HTC_TST_DSD	Age/sex: 20-24 Female	162
HTC_TST_DSD	Age/sex: 25-49 Female	138
HTC_TST_DSD	Age/sex: 50+ Female	23
HTC_TST_DSD	Sum of Age/Sex disaggregates	6,681
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	9
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	63
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	95
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	110
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	48
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	16
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	24
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	28
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	11
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,199
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,240
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	24
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	463
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,223
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,703
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,926
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	17

	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	316
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	4
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	79
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	6
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	245
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	1,088
HTC_TST_DSD	Service Delivery Point (Facility): VCT	1,260
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	4,492
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	86
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	500
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	500
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	15
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	285
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	190
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	315



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	500
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	180
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	120
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,147
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	12
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	676
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	8
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	451
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	207
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	344
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	310
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	34
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other	0



	(not Xpert)	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,912
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	19
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,128
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	13
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	752
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	32
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,880
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,912
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	366
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	218
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	146
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	366
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	311
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	364
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	185
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	124



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	216
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	146

Implementing Mechanism Details

Mechanism ID: 17431	Mechanism Name: Support Laboratory Diagnosis and Monitoring to Scale up and Improve HIV/AIDS Care and Treatment Services in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:
Total All Funding Sources: 1,128,266	



Applied Pipeline Amount: 500,000	
Total All Funding Sources and Applied Pipeline Amount: 1,628,266	
Funding Source	Funding Amount
GHP-State	1,128,266

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
Motor Vehicles: Purchased	50,000

Budget Code Information

Mechanism ID: 17431			
Mechanism Name: Support Laboratory Diagnosis and Monitoring to Scale up and Improve HIV/AIDS Care and Treatment Services in the Kingdom of Lesotho under			
Prime Partner Name: the President's Emergency Plan for AIDS Relief (PEPFAR)			
University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	49,827	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	63,166	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	327,076	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	665,614	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	22,583	0
-----------	------	--------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	260
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	116
PMTCT_EID_DSD	Sum of Infant Age disaggregates	376
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	7
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	7
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	31,657
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	35,174
TX_PVLS_DSD	Numerator: Indication: Routine	31,657
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	35,174
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	913
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	10,206
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,248
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	19,293
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,401
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	11,126
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,342



TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	21,053
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	9
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	9
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	9
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	9
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	9
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	9
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9



LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	9
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	9
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	24
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	24
LAB_PT_TA	CD4: Number of laboratories that perform this testing	24
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	101
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	101
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	101
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	600,000
INVS_COMD	Number of HIV CD4 Reagents purchased	100,000
INVS_COMD	Number of HIV Viral Load Reagents purchased	500,000
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	100,000
INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	500,000



Implementing Mechanism Details

Mechanism ID: 17432	Mechanism Name: Support Ministry of Health to Strengthen Health Systems and Coordinate HIV/AIDS Prevention, Care and Treatment Programs in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 3,572,811	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,572,811	
Funding Source	Funding Amount
GHP-State	3,572,811

Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
Motor Vehicles: Purchased	50,000

Budget Code Information

Mechanism ID:	17432
Mechanism Name:	Support Ministry of Health to Strengthen Health Systems and Coordinate HIV/AIDS Prevention, Care and Treatment Programs in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)
Prime Partner Name:	Ministry of Health (MOH)



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	269,825	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	337,281	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,563,336	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	202,369	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,632
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	890
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,522
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	69
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	8
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	109,136



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	121,259
TX_PVLS_DSD	Numerator: Indication: Routine	109,136
TX_PVLS_DSD	Denominator: Indication: Routine	121,259
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3,532
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	36,620
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	4,011
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	64,978
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	4,343
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	41,216
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	4,454
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	71,023
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	2
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	2
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	1
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1



LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	2
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	8
LAB_PT_TA	CD4: Number of laboratories that perform this testing	8
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8



LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	8
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	8
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	8
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	8
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	8
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	8
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	2,200,000
INVS_COMD	Number of HIV CD4 Reagents purchased	400,000
INVS_COMD	Number of HIV Viral Load Reagents purchased	1,800,000
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	400,000
INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	1,800,000

Implementing Mechanism Details



Mechanism ID: 17549	Mechanism Name: TSEPO
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 109,873	
Applied Pipeline Amount: 2,971,953	
Total All Funding Sources and Applied Pipeline Amount: 3,081,826	
Funding Source	Funding Amount
GHP-State	109,873

Cross-Cutting Budget Attribution(s)

Gender: GBV	5,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Human Resources for Health	109,873

Budget Code Information

Mechanism ID: 17549			
Mechanism Name: TSEPO			
Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	109,873	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	CIRC	0	0
------------	------	---	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	36,081
VMMC_CIRC_DSD	By Age: 15-19	12,230
VMMC_CIRC_DSD	By Age: 20-24	11,475
VMMC_CIRC_DSD	By Age: 25-29	12,376
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	23,705
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	36,081
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	30,081
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	6,000
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	28,866
HTC_TST_DSD	Age/sex: 15-19 Male	9,784
HTC_TST_DSD	Age/sex: 20-24 Male	9,180
HTC_TST_DSD	Age/sex: 25-49 Male	9,902
HTC_TST_DSD	Sum of Age/Sex disaggregates	28,866
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	28,866

Implementing Mechanism Details

Mechanism ID: 18020	Mechanism Name: Providing Universal Services for HIV/AIDS (PUSH)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 9,030,719	
Applied Pipeline Amount: 1,084,388	
Total All Funding Sources and Applied Pipeline Amount: 10,115,107	
Funding Source	Funding Amount
GHP-State	9,030,719

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,614,000
Food and Nutrition: Policy, Tools, and Service Delivery	200,000
Motor Vehicles: Purchased	150,000
Gender: Gender Equality	30,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Gender: GBV	15,000
Focus Area:	Post GBV Care
Water	200,000

Budget Code Information

Mechanism ID: 18020			
Mechanism Name: Providing Universal Services for HIV/AIDS (PUSH)			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	586,159	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,366,850	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	598,009	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	475,818	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	312,695	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,694,038	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	997,150	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,693
PMTCT_ART_DSD	New on ART	3,253
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,104
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,693
PMTCT_STAT_DSD	Number of new ANC and L&D clients	20,880
PMTCT_STAT_DSD	By: Known positives at entry	3,410
PMTCT_STAT_DSD	By: Number of new positives identified	2,228



PMTCT_STAT_DSD	Sum of Positives Status disaggregates	5,638
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	13
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	524
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	732
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	17
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	876
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	1,017
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	166
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	5,438
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	6,576
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	8,692
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	8
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	1,496
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	960
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	2
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	120
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	5,120
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	6,184



PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	8,254
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	15
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	333,969
HTC_TST_DSD	Age/sex: 10-14 Male	10,754
HTC_TST_DSD	Age/sex: 15-19 Male	6,968
HTC_TST_DSD	Age/sex: 20-24 Male	5,889
HTC_TST_DSD	Age/sex: 25-49 Male	58,649
HTC_TST_DSD	Age/sex: 50+ Male	32,584
HTC_TST_DSD	Age/sex: 10-14 Female	10,780
HTC_TST_DSD	Age/sex: 15-19 Female	10,547
HTC_TST_DSD	Age/sex: 20-24 Female	8,784
HTC_TST_DSD	Age/sex: 25-49 Female	88,026
HTC_TST_DSD	Age/sex: 50+ Female	55,113
HTC_TST_DSD	Sum of Age/Sex disaggregates	288,094
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	803
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	583
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	910
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	12,304
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	3,386
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	812
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	887
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,386
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	18,366
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	5,714
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	29,110
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	104,092
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	38,315



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	162,454
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	67,425
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	266,546
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	333,971
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,753
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	17,183
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2,236
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	26,366
HTC_TST_DSD	Test Result by Age: Positive: <1	397
HTC_TST_DSD	Test Result by Age: Positive: 1-9	1,991
HTC_TST_DSD	Age/sex: <1	13,396
HTC_TST_DSD	Age/sex: 1-9	32,479
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	2,344
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	197,114
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	17,780
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	95,401
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	32,317
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	8,755
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	8,755
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	257



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,760
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	209
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,529
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,895
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	5,895
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	153
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,226
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	130
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,386
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	94,284

TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,355
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	31,354
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,355
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	58,220
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3,969
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,969
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,969
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,802
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,475
PMTCT_EID_DSD	Sum of Infant Age disaggregates	5,277
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	43
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	19
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	115,404
TX_CURR_DSD	Age/Sex: 15-19 Male	1,387
TX_CURR_DSD	Age/Sex: 15-19 Female	2,078
TX_CURR_DSD	Sum of age/sex disaggregates	3,465
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,874
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	43,186
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,877
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	66,467
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,751
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	109,653



TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	115,404
TX_CURR_DSD	Age/Sex: <1	570
TX_CURR_DSD	Age/Sex: <1-9	2,877
TX_CURR_DSD	Age/Sex: 10-14 Male	1,149
TX_CURR_DSD	Age/Sex: 10-14 Female	1,156
TX_CURR_DSD	Age/Sex: 20-24 Male	2,307
TX_CURR_DSD	Age/Sex: 25-49 Male	30,931
TX_CURR_DSD	Age/Sex: 50+ Male	8,565
TX_CURR_DSD	Age/Sex: 20-24 Female	3,462
TX_CURR_DSD	Age/Sex: 25-49 Female	46,374
TX_CURR_DSD	Age/Sex: 50+ Female	14,548
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	54,672
TX_NEW_DSD	By Age/Sex: <1	272
TX_NEW_DSD	By Age/Sex: 1-9	1,365
TX_NEW_DSD	By Age/Sex: 10-14 Male	546
TX_NEW_DSD	By Age/Sex: 15-19 Male	655
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,088
TX_NEW_DSD	By Age/Sex: 25-49 Male	14,653
TX_NEW_DSD	By Age/Sex: 50+ Male	4,070
TX_NEW_DSD	By Age/Sex: 10-14 Female	546
TX_NEW_DSD	By Age/Sex: 15-19 Female	984
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,640
TX_NEW_DSD	By Age/Sex: 25-49 Female	21,965
TX_NEW_DSD	By Age/Sex: 50+ Female	6,885
TX_NEW_DSD	Sum of Age/Sex disaggregates	53,032
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,355
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	20,479
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,355
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	31,483
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	54,672
TX_PVLS_DSD	Number of adults and pediatric patients on ART with	82,958

	suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	92,275
TX_PVLS_DSD	Numerator: Indication: Routine	82,958
TX_PVLS_DSD	Denominator: Indication: Routine	92,275
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,069
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	31,033
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,068
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	47,776
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,319
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	34,187
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,319
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	53,450
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	35,115
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	42,792
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	347
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	694
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	350
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	190



	months after initiating ART	
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	585
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,794
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,490
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	347
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,211
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,626
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,389
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,092
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	425
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	847



TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	431
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	239
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	715
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,727
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,816
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	424
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,467
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of	4,409



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17,520
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,772
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	871
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,075
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	865
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22,302
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,062
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	13,494



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,062
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27,174

Implementing Mechanism Details

Mechanism ID: 18048	Mechanism Name: Global Health Supply Chain Management
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	
Applied Pipeline Amount: 1,000,000	
Total All Funding Sources and Applied Pipeline Amount: 2,000,000	
Funding Source	Funding Amount
GHP-USAID	1,000,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	250,000
----------------------------	---------



Budget Code Information

Mechanism ID:	18048		
Mechanism Name:	Global Health Supply Chain Management		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	460,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	160,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18143	Mechanism Name: 4Children – Coordinating Comprehensive Care for Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18143		
Mechanism Name:	4Children – Coordinating Comprehensive Care for Children		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	46,839
OVC_SERV_DSD	Age/Sex: 18+ Female	26,559
OVC_SERV_DSD	Sum of Age/Sex disaggregates	26,559
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	7,755
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	7,805



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	645
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	16,207
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	4,075
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	3,692
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	6,760
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	20,280

Implementing Mechanism Details

Mechanism ID: 18227	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18235	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: USG Core
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	769,015
GHP-USAID	230,985



Cross-Cutting Budget Attribution(s)

Key Populations: FSW	150,000
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	200,000
Gender: Gender Equality	30,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information

Budget Code Information

Mechanism ID: 18235			
Mechanism Name: EQUIP			
Prime Partner Name: Right To Care, South Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	900,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	100,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_ART_DSD	New on ART	0
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0
PMTCT_STAT_DSD	By: Known positives at entry	0
PMTCT_STAT_DSD	By: Number of new positives identified	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	0



	new positives: 25-49	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	47,505
HTC_TST_DSD	Age/sex: 10-14 Male	0
HTC_TST_DSD	Age/sex: 15-19 Male	0
HTC_TST_DSD	Age/sex: 20-24 Male	2,930
HTC_TST_DSD	Age/sex: 25-49 Male	38,278
HTC_TST_DSD	Age/sex: 50+ Male	6,300
HTC_TST_DSD	Age/sex: 10-14 Female	0
HTC_TST_DSD	Age/sex: 15-19 Female	0
HTC_TST_DSD	Age/sex: 20-24 Female	0
HTC_TST_DSD	Age/sex: 25-49 Female	0
HTC_TST_DSD	Age/sex: 50+ Female	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	47,508
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	294
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	3,832
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	631
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	0



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	47,505
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	47,505
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	47,505
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,757
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	0
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	0
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	47,505
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	0
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	0
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The	0



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	0
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	0
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_DSD	Sum of Infant Age disaggregates	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0
TX_CURR_DSD	Age/Sex: 15-19 Male	0
TX_CURR_DSD	Age/Sex: 15-19 Female	0
TX_CURR_DSD	Sum of age/sex disaggregates	0
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0



TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	0
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	0
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	0
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	0
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	0
TX_CURR_DSD	Age/Sex: 10-14 Male	0
TX_CURR_DSD	Age/Sex: 10-14 Female	0
TX_CURR_DSD	Age/Sex: 20-24 Male	0
TX_CURR_DSD	Age/Sex: 25-49 Male	0
TX_CURR_DSD	Age/Sex: 50+ Male	0
TX_CURR_DSD	Age/Sex: 20-24 Female	0
TX_CURR_DSD	Age/Sex: 25-49 Female	0
TX_CURR_DSD	Age/Sex: 50+ Female	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,801
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	0
TX_NEW_DSD	By Age/Sex: 10-14 Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	0
TX_NEW_DSD	By Age/Sex: 20-24 Male	234
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,062
TX_NEW_DSD	By Age/Sex: 50+ Male	504
TX_NEW_DSD	By Age/Sex: 10-14 Female	0
TX_NEW_DSD	By Age/Sex: 15-19 Female	0
TX_NEW_DSD	By Age/Sex: 20-24 Female	0
TX_NEW_DSD	By Age/Sex: 25-49 Female	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,800
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,800
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	0
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,800
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	0
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	0
TX_PVLS_DSD	Numerator: Indication: Routine	0
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	0
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and	0



	children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who	0



	have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	0



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	0



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0

Implementing Mechanism Details

Mechanism ID: 18240	Mechanism Name: Vodafone
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Vodafone Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-USAID	0

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: 18240			
Mechanism Name: Vodafone			
Prime Partner Name: Vodafone Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	79,500
HTC_TST_DSD	Age/sex: 10-14 Male	12,592
HTC_TST_DSD	Age/sex: 15-19 Male	3,817
HTC_TST_DSD	Age/sex: 20-24 Male	3,435
HTC_TST_DSD	Age/sex: 25-49 Male	3,049
HTC_TST_DSD	Age/sex: 50+ Male	2,295
HTC_TST_DSD	Age/sex: 10-14 Female	13,642
HTC_TST_DSD	Age/sex: 15-19 Female	4,546
HTC_TST_DSD	Age/sex: 20-24 Female	2,480
HTC_TST_DSD	Age/sex: 25-49 Female	3,307
HTC_TST_DSD	Age/sex: 50+ Female	3,306
HTC_TST_DSD	Sum of Age/Sex disaggregates	52,469
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	315
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	128
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	344



HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	260
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	363
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	339
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	316
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	308
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	538
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	452
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	677
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	27,031
HTC_TST_DSD	Service Delivery Point (Community): Index testing	6,402
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	18,658
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	52,807
HTC_TST_DSD	Service Delivery Point (Community): Other	1,633

Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing			149,114	0	149,114	149,114
Computers/IT Services			142,095	0	142,095	142,095
ICASS			941,850	0	941,850	941,850
Management Meetings/Profes			80,276	35,000	80,276	115,276



sional Development						
Non-ICASS Administrative Costs			117,629	0	117,629	117,629
Staff Program Travel		0	125,678	100,000	125,678	225,678
USG Staff Salaries and Benefits - Internationally Recruited		0	1,187,013	900,000	1,187,013	2,087,013
USG Staff Salaries and Benefits - Locally Recruited		0	429,534	0	429,534	429,534
Total	0	0	3,173,189	1,035,000	3,173,189	4,208,189

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		2,000		0	2,000	2,000
ICASS		14,252		16,881	14,252	31,133
Management Meetings/Profes		3,119		3,695	3,119	6,814



sional Development						
Non-ICASS Administrative Costs		2,408		2,852	2,408	5,260
Non-ICASS Motor Vehicles		20,000		0	20,000	20,000
Staff Program Travel		6,082		7,205	6,082	13,287
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		22,163		26,250	22,163	48,413
Total	0	70,024	0	56,883	70,024	126,907

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		72,637		107,017	72,637	179,654



Computers/IT Services		37,116		20,484	37,116	57,600
ICASS		0		317,125	0	317,125
Institutional Contractors	0	108,926		92,922	108,926	201,848
Management Meetings/Professional Development		12,734		11,266	12,734	24,000
Non-ICASS Administrative Costs		156,807		106,871	156,807	263,678
Staff Program Travel	0	98,596		94,404	98,596	193,000
USG Staff Salaries and Benefits - Internationally Recruited	489,921	0		550,000	489,921	1,039,921
USG Staff Salaries and Benefits - Locally Recruited	22,579	135,439		0	158,018	158,018
Total	512,500	622,255	0	1,300,089	1,134,755	2,434,844

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied
-------------------------------	-----	-----------	-----------	------------------	-------	---



						Pipeline Amount
Computers/IT Services		10,000		0	10,000	10,000
ICASS		89,047		0	89,047	89,047
Management Meetings/Professional Development		25,000		0	25,000	25,000
Non-ICASS Administrative Costs		66,503		58,497	66,503	125,000
Staff Program Travel		30,000		0	30,000	30,000
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		81,432		0	81,432	81,432
Total	0	301,982	0	58,497	301,982	360,479

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied

Approved



						Pipeline Amount
Non-ICASS Administrative Costs		52,407		0	52,407	52,407
Peace Corps Volunteer Costs		437,666		0	437,666	437,666
Staff Program Travel		12,367		0	12,367	12,367
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		47,560		0	47,560	47,560
Total	0	550,000	0	0	550,000	550,000